THE MEASUREMENT of oestrogen receptors (RE) in human breast tumours has identified a group of patients with receptor-negative (RE-) tumours who have a very low response rate to hormonal manipulation. In contrast 60% of patients with receptor-positive (RE+) tumours respond to endocrine treatment (McGuire et al., 1975) . It is clear that more accurate identification of hormone-sensitive tumours would allow better selection of treatment than is possible at present, and various additional measurements have been suggested to help improve the positive predictive value of RE assays, such as simultaneous measurement of progesterone receptor (RP) (Horwitz et al., 1975) . In addition to a role for endocrine therapy, a recent survey has suggested that RE measurements might also be helpful in selecting patients for chemotherapy (Lippman et al., 1978) . In this report some of the clinical correlations of cytosol RE and RP (4) . The response to treatment was assessed using the objective criteria of the British Breast Group (Hayward et al., 1977) . Thus disappearance of all detectable disease was labelled "'complete remission", and regression by at least 50% of at least half the detectable lesions and with no growth of any lesion or appearance of new disease was classed "partial remission". Static disease was defined as ''no progress in any detectable lesion" and "no appearance of new metastases" when the disease had been advancing before treatment was begun. Appearance of a new site of disease, or growth in any existing lesion, was labelled "progressive disease". At least 3 months of observation were required before a remission category was assigned. scintigramns and relevant X-rays completed at 6-monthly intervals; bone disease was confirmed by radiographs in all cases. Clinical assessment was performed by a panel using the patient's notes, relevant X-rays and bone scintigrams. An independent referee (E.P.A.) who did not know the patients was included, and the receptor status of the patients was not disclosed during discussion.
Biopsy samples from metastatic sites were measured for RE and RP as described (Holdaway & Mountjoy, 1978) , with some recent assay modifications. Unlabelled steroids were added to tubes in 100% ethanol and dried under an N2 stream; labelled steroid was later added to cytosol preparations in 2% ethanol, giving a final ethanol concentration of 0.004%0. Recently, tumour samples have been prepared for assay by pulverization in the frozen state with a stainless-steel pestle and mortar, and the resultant powder homogenized as previously described (Holdaway & Mountjoy, 1978) . A significant amount of receptor was arbitrarily defined as 5 fmol/mg cytosol protein or more (RE) or 3 finol/mg cytosol protein or more (RP). Statistical evaluation was carried out by a non-parametric method, the Wilcoxon rank sum test, and population groups were compared using Fisher's modification of Yates's chi-squared test (Langley, 1968) .
The frequency of objective response to treatment is shown in Fig. 1 . Patients with RE+ tumours had a significantly greater response rate overall to endocrine therapy than those with RE-tumours. The difference between the RE+ and RE-groups remains significant, whether or not patients with static disease are included in the remission category. Two of the three RE-patients who responded to endocrine treatment were pre-menopausal, and one of these tumours was RP+, suggesting that this was possibly a "false-negative RE" tumour (see below). By comparison with the results for endocrine treatment, there was no significant difference in remission rate between RE+ and RE-tumours with chemotherapy or combined endocrine treatment and chemotherapy. In 57 treatments in which both RE and RP measurements were available, RP assay did not improve the discrimination between responding and non-responding patient groups (Table I ). In particular, the response rate in the RE+ group was equally divided between those tumours which were RP+ and RP-. On one occasion RP measurement provided useful information in the single patient in the series with a tumour which was RE-RP+; this patient had a complete remission with tamoxifen therapy. The influence of the tumc tion of RE on response rate therapy is shown in Fig. 2 with metastases at initial presentation) showed that RE+ patients had experienced ur concentra-a significantly longer disease-free interval -to endocrine (37 + 28 months) than RE-patients and compared (22.7 + 20 months) (P < 0 002).
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was very brief and treatment usually led to disease becoming static without significant objective tumour regression. These observations favour the theory that objective response to endocrine therapy in RE-tumours probably results from a response in a small proportion of RE+, hormonally responsive cells in the tumour.
The presence of progesterone receptor (RP) has been proposed as a means of identifying tumours biologically sensitive to oestrogen and hence as a method of improving the discrimination of RE measurements (Horwitz et al., 1975) . However, in the present series it did not appear that RP assays added significantly to the discrimination of RE measurements, with the exception of one RE-RP+ tumour. From the present data such a tumour should be classified as if RE+. As a further means of improving the positive predictive capacity of receptor assays it has been suggested that tumours with a high RE content arc particularly likely to be hormone responsive . In the present study, when the tumour RE content was > 50 fmol/mg protein, about 80% of the patients responded to hormonal treatment (Fig. 2) . This observation thus indicates one method of improving the accuracy of prediction of hormonally responsive tumours.
It has recently been claimed that patients with RE-metastatic tumours have a significantly increased response rate to chemotherapy compared with RE+ tumours (Lippman et al., 1978) . However, discrepant reports have appeared (Kiang et al., 1978) . In the present series there was no apparent difference in the rate of response to chemotherapy between RE+ and RE-groups, although the total number of patients treated was small. It was striking, however, that the duration of remission in RE-patients responding to treatment was significantly longer than in responding RE+ patients. This may in part support the contention of Lippman et al. (1978) , if, as they propose, chemotherapy is more effective against the proportion of tumours which are RE-.
